Spyre Therapeutics, Inc. - Common Stock SYRE 深 沪
已收盘 09-19 16:00:00 美东时间
14.88
-0.440
-2.87%
华盛通- 最 高15.46
- 今 开15.46
- 成交量 96.80万股
- 最 低 14.635
- 昨 收 15.32
- 总市值 8.99亿
- 52周最高 40.26
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 10.91
- 委 比 -93.56%
- 总股本 6040.10万
- 历史最高 318.75
- 量 比 1.36
- 振 幅 5.39%
- 历史最低 2.66
- 每 手 1
- 风险率 6.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
First Patient Dosed In Spyre Therapeutics Phase 2 Trial Of SPY072 For Rheumatic Diseases
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
09-15 20:02
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
Spyre Therapeutics has initiated a Phase 2 basket trial of SPY072, an investigational antibody targeting TL1A, for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY072, designed for quarterly or twice-yearly subcutaneous dosing, aims to provide superior convenience and durability. The SKYWAY trial is expected to deliver proof-of-concept data for all three indications in 2026. SPY072's ...
09-15 12:00
Spyre Therapeutics Q2 EPS $(0.49) Beats $(0.77) Estimate
Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.77) by 35.95 percent. This is a 16.95 percent increase over losses of $(0.59) per share
08-06 04:39
外国投资者保持对越南投资信心 继续开展各大规模项目
（来源：伟迪东盟国际物流） 越通社河内 ——在仍存在对美国关税政策可能带来影响的担忧的情况下，外国投资者依然对越南充满信心，持续在越南推进多个大型项...
07-16 12:01
Spyre reports results from early stage TL1A antibody trials
Spyre Therapeutics (NASDAQ:SYRE) reported updates from its initial early stage studies involving SPY002 and SPY072, the company's new monoclonal antibodies designed to target TL1A. In the studies, SPY...
06-17 21:46
Spyre Therapeutics To Announce Interim Phase 1 SPY002 Trial Results For IBD On June 17, 2025, With Conference Call And Webcast At 8:00am ET
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
06-17 04:10
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engin...
06-07 04:05
凯雷Q1坚定押注StandardAero(SARO.US) 清仓Robinhood(HOOD.US)
凯雷第一季度持仓总市值为38.0亿美元，上一季度总市值为41.5亿美元，环比下降8%。
05-16 17:23
Spyre Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
Spyre Therapeutics shares are trading higher after the company reported better-...
05-10 01:08
